Technical Sourcing Expands Its ATP Intellectual Property Portfolio

MISSOULA, Mont. (September 22, 2003) – Technical Sourcing International, Inc. (TSI), a leading developer, producer, and marketer of nutraceutical ingredients, today announced that it has recently acquired an exclusive worldwide license to an extensive portfolio of both domestic and foreign patents directed to delivery of Adenosine 5’-Triphosphate (ATP).

Under an exclusive license agreement with Eliezer Rapaport, Ph.D., TSI has acquired certain right, title, and interest in and to six issued patents and four pending patent applications with the right to grant sublicenses for the same. The licensed patent portfolio of Dr. Rapaport includes, for example, U.S. Patent No. 5,227,371 entitled “Utilization of Adenine Nucleotides and/or Adenosine and Inorganic Phosphate for Elevation of Liver, Blood, and Blood Plasma ATP Concentrations” and U.S. Patent No. 5,049,372 entitled “Anticancer Activities in a Host by Increasing Blood and Plasma ATP.” TSI also has developed its own domestic and foreign patent pending ATP technology directed to exogenous administration of ATP for reducing muscle fatigue and for enhancing human performance. The combination of acquiring the exclusive license to the Rapaport patents and its own internally developed ATP technologies demonstrates TSI’s emerging role as a leader in developing, producing, and marketing ATP as a nutraceutical ingredient. In this regard, TSI considers its patent portfolio and developing technologies directed to ATP to be a valuable asset of the company and it is, therefore, committed to protecting and preserving those rights against any potential infringers.

Dr. Rapaport is widely recognized as an expert in adenosine nucleotides. He received his doctorate from the Johns Hopkins University in 1971 and, since that time, has been on the faculties of Harvard Medical School, Boston University School of Medicine, and the Worcester Foundation for Experimental Biology. Dr. Rapaport has also been a consultant to several pharmaceutical and biotechnology companies and is currently sharing his expertise and providing consulting services to TSI. Dr. Rapaport has published more than 50 scientific papers and is credited with the seminal discovery that organ, red blood cell (total blood), and blood plasma (extracellular) pools of ATP can be expanded by systemic administration of ATP.

Larry Kolb, TSI’s President and co-founder, commented on the arrangement, “Dr. Rapaport is one of the world’s foremost authorities on ATP having devoted over 30 years to the study of its physiological action. This deal provides for the first legitimate entry of ATP into the marketplace.” Kolb continued in saying, “We are very pleased to have secured this opportunity for TSI and its customers. It further confirms our commitment to producing and supplying groundbreaking ingredients to provide our manufacturing partners a significant advantage in bringing sound, efficacious products to market. ATP is the ‘best in class’ performance-enhancing ingredient and will provide tremendous health benefits for millions.”

About Technical Sourcing International, Inc.

TSI is a leading developer, producer, and marketer of nutraceutical ingredients to the dietary supplement, pharmaceutical, and food and beverage industries. Among the numerous botanical, marine, and natural product extracts, as well as synthesized compounds in its ingredient portfolio, the company also offers several trademarked consumer ingredient brands, including OSTIVONEÒ, MSV 60Ò, PROMILIN™, and PUREFLEX® Chondroitin Sulfate and Glucosamine. The company is based in Missoula, Montana, and can be reached at (406) 549-9123 or

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.